Medical management of intermittent claudication

Vascular and Endovascular Surgery

Volumn 38, Issue 5, 2004, Pages 391-399

  Casey, Kevin ^a,b   Tonnessen, Britt H ^a,b   Sternbergh III, W Charles ^a,b   Money, Samuel R ^a,b  

^a Ochsner Clinic Foundation ^*

^b OCHSNER CLINIC FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; ARGININE; ATORVASTATIN; BERAPROST; BUFLOMEDIL; CALCIUM CHANNEL BLOCKING AGENT; CARNITINE; CILOSTAZOL; CLOPIDOGREL; DILTIAZEM; ECRAPROST; ERYTHROMYCIN; GINKGO BILOBA EXTRACT; KETOCONAZOLE; LIVER ENZYME; NAFTIDROFURYL OXALATE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PARACETAMOL; PENTOXIFYLLINE; PROSTAGLANDIN DERIVATIVE; PROSTAGLANDIN E1; SIMVASTATIN; VASODILATOR AGENT; VERAPAMIL;

ADJUVANT THERAPY; ARTERY DISEASE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CHELATION THERAPY; CLINICAL FEATURE; CLINICAL TRIAL; COMORBIDITY; DIARRHEA; DISEASE SEVERITY; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME BLOOD LEVEL; EXERCISE; FOLLOW UP; FOOD DRUG INTERACTION; HEADACHE; HEART INFARCTION; HEART PALPITATION; HUMAN; INTERMITTENT CLAUDICATION; KINESIOTHERAPY; META ANALYSIS; NAUSEA; RASH; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; STROKE; THROMBOSIS; TREATMENT OUTCOME; VASCULAR SURGERY; VOMITING;

CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; CEREBROVASCULAR DISORDERS; EXERCISE; HUMANS; INTERMITTENT CLAUDICATION; RISK FACTORS;

EID: 5444255246     PISSN: 15385744     EISSN: None     Source Type: Journal    
DOI: 10.1177/153857440403800501     Document Type: Review

References (51)

1. Belch JF, Topol EJ, Agnelli G, et al: Critical issues in peripheral arterial disease detection and management: A call to action. Arch Intern Med 163:884-892, 2003.
2. Fowkes FGR: Epidemiology of peripheral vascular disease. Atherosclerosis 131:S29-S31, 1997.
3. Gardner AW, Poehlman ET: Exercise rehabilitation programs for the treatment of claudication pain. JAMA 274:975-980, 1995.
4. Kannel WB, Skinner JJ, Schwartz MJ, et al: Intermittent claudication: Incidence in the Framingham study. Circulation 41:875-883, 1970.
5. Hirsch AT, Halverson SL, Treat-Jacobson D, et al: The Minnesota regional peripheral arterial disease screening program: Toward a definition of community standards of care. Vasc Med 6:87-96, 2001.
6. Leng GC, Fowkes FGR: The Edinburgh claudication questionnaire: An improved version of the WHO/rose questionnaire for use in epidemiological surveys. J Clin Epidemiol 45:1101-1109, 1992.
7. Regensteiner JG, Hiatt WR: Exercise rehabilitation for patients with peripheral arterial disease. Exerc Sport Sci Rev 23:1-24, 1995.
8. Regensteiner JG, Gardner A, Hiatt WR: Exercise testing and exercise rehabilitation for patients with peripheral arterial disease: Status in 1997. Vasc Med 2:147-155, 1997.
9. Dormandy J, Heeck L, Vig S: The natural history of claudication: Risk to life and limb. Semin Vasc Surg 12:123-137, 1999.
10. Dormandy J, Mahir M, Ascady G, et al: Fate of the patient with chronic leg ischaemia. J Cardiovasc Surg 30:50-57, 1989.
11. Bloor K: Natural history of arteriosclerosis of the lower extremities. Ann R Coll Surg Engl 28:36-51, 1961.
12. Imparato AM, Kim GE, Davidson T, et al: Intermittent claudication: Its natural course. Surgery 78:795-799, 1975.
13. Aquino R, Johnnides C, Makaroun M, et al: Natural history of claudication: Long-term serial follow-up study of 1,244 claudicants. J Vasc Surg 34:962-970, 2001.
14. Leng GC, Lee AJ, Fowkes GR, et al: Incidence, natural history and cardiovascular events in symptomatic and asymptomatic peripheral arterial disease in the general population. Int J Epidemiol 25:1172-1181, 1996.
15. Tsai JC, Chan P, Wang CH, et al: The effects of exercise training on walking function and perception of health status in elderly patients with peripheral occlusive disease. Intern Med 252:448-455, 2002.
16. Hiatt WR, Regensteiner JG, Hargarten ME, et al: Benefit of exercise conditioning for patients with peripheral arterial disease. Circulation 81:602-609, 1990.
17. Patterson RB, Pinto B, Marcus B, et al: Value of a supervised exercise program for the therapy of arterial claudication. J Vasc Surg 25:312-319, 1997.
18. Stewart KJ, Hiatt WR, Regensteiner JG, et al: Exercise training for claudication. N Engl J Med 347: 1941-1951, 2002.
19. Alpert JS, Larsen OA, Lassen NA: Exercise and intermittent claudication: Blood flow in the calf muscle during walking studied by the xenon-133 clearance method. Circulation 39:353-359, 1969.
20. Dahlof A, Holm J, Schersten T, et al: Peripheral Arterial Insufficiency: Effect of physical training on walking tolerance, calf blood flow, and blood flow resistance. Scand J Rehab Med 8:19-26, 1976.
21. Lewis HD, Davis JW, Archibald DG, et al: Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. N Engl J Med 309:396-403, 1983.
22. Clagett GP, Graor RA, Salzman EW: Antithrombotic therapy in peripheral arterial occlusive disease. Chest 102(suppl):516S-528S, 1992.
23. Goldhaber SZ, Manson JE, Stampfer MJ, et al: Low-dose aspirin and subsequent peripheral arterial surgery in the physicians' health study. Lancet 340: 143-145, 1992.
24. CAPRIE Steering Committee: A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348:1329-1339, 1996.
25. Porter JM, Cutler BS, Lee BY, et al: Pentoxifylline efficacy in the treatment of intermittent claudication: Multicenter controlled double-blind trial with objective assessment of chronic occlusive arterial disease patients. Am Heart J 104:66-72, 1982.
26. Reich T, Gillings D: Effects of pentoxifylline on severe intermittent claudication. Angiology 38:651-656, 1987.
27. DeSanctis MT, Cesarone MR, Belcaro G, et al: Treatment of long-distance intermittent claudication with pentoxifylline: A 12-month, randomized trial. Angiology 53(suppl):S13-S17, 2002.
28. Cesarone MR, Belcaro G, Nicolaides AN, et al: Treatment of severe intermittent claudication with pentoxifylline: A 40-week, controlled, randomized trial. Angiology 53(suppl):S1-S5, 2002.
29. Donaldson DR, Hall TJ, Kester RC, et al: Does oxpentifylline have a place in the treatment of intermittent claudication? Curr Med Res Opin 9:35-40, 1984.
30. Ernst E, Kollar L, Resch KL: Does pentoxifylline prolong walking distance in exercised claudicants? A placebo-controlled double-blind trial. Angiology 43:121-125, 1992.
31. Hood SC, Moher D, Barber GG: Management of intermittent claudication with pentoxifylline: Meta-analysis of randomized controlled trials. Can Med Assoc J 155:1053-1059, 1996.
32. Dawson, DL, Cutler BS, Meissner MH, et al: Cilostazol has beneficial effects in treatment of intermittent claudication: Results from a multicenter, randomized, prospective, double-blind trial. Circulation 98:678-686, 1998.
33. Money SR, Herd JA, Isaacsohn JL, et al: Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. J Vasc Surg 27:267-275, 1998.
34. Beebe HG, Dawson DL, Cutler BS, et al: A new pharmacological treatment for intermittent claudication: Results of a randomized, multicenter trial. Arch Intern Med 159:2041-2050, 1999.
35. Elam MB, Heckman J, Crouse JR, et al: Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arterioscler Thromb Vasc Biol 18:1942-1947, 1998.
36. Dawson DL, Cutler BS, Hiatt WR, et al: A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med 109:523-530, 2000.
37. Moody AP, Al-Khaffaf HS, Lehert P, et al: An evaluation of patients with severe intermittent claudication and the effect of treatment with naftidrofuryl. J Cardio Pharm 23(suppl);S44-S47, 1994.
38. Kieffer E, Bahnini A, Mouren X, et al: A new study demonstrates the efficacy of naftidrofuryl in the treatment of intermittent claudication: Findings of the Naftidrofuryl Clinical Ischemia Study (NCIS). Int Angiol 20:58-65, 2001.
39. 1 prodrug, in patients with intermittent claudication. Circulation 95:2298-2302, 1997.
40. 2 analogue, for intermittent claudication. Circulation 102:426-431, 2000.
41. 2 analogue. J Am Coll Cardiol 41:1679-1686, 2003.
42. Brevetti G, Diehm C, Lambert D, et al: European multicenter study on propionyl-L-carnitine in intermittent claudication. J Am Coll Cardiol 34:1618-1624, 1999.
43. Hiatt WR, Regensteiner JG, Creager MA, et al: Propionyl-L-carnitine improves exercise performance and functional status in patients with claudication. Am J Med 110:616-622, 2001.
44. Boger RH, Bode-Boger SM, Thiele W, et al: Restoring vascular nitric oxide formation by L-arginine improves the symptoms of intermittent claudication in patients with peripheral arterial occlusive disease. J Am Coll Cardiol 1998;32:1336-1344.
45. Mondillo S, Ballo P, Barbati R, et al: Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascular disease. Am J Med 114:359-364, 2003.
46. Mohler ER, Hiatt WR, Creager MA: Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation 108:1481-1486, 2003.
47. Bagger JP, Helligsoe P, Randsbaek F, et al: Effect of verapamil in intermittent claudication: A randomized, double-blind, placebo-controlled, cross-over study after individual dose-response assessment. Circulation 95:411-414, 1997.
48. Guldager B, Jorgensen PJ, Grandjean P: Metal excretion and magnesium retention in patients with intermittent claudication treated with intravenous disodium EDTA. Clin Chem 42:1938-1942, 1996.
49. van Rij AM, Solomon C, Packer SG, et al: Chelation therapy for intermittent claudication. A double-blind, randomized, controlled trial. Circulation 90:1194-1199, 1994.
50. Pittler MH, Ernst E: Ginkgo biloba extract for the treatment of intermittent claudication: A meta-analysis of randomized trials. Am J Med 108:276-281, 2000.
51. Chacon-Quevedo A, Eguaras MG, Calleja F, et al: Comparative evaluation of pentoxifylline, buflomedil, and nifedipine in the treatment of intermittent claudication of the lower limbs. Angiology 45:647-653, 1994.